Free Trial
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Price, News & Analysis

Kaleido Biosciences logo

About Kaleido Biosciences Stock (NASDAQ:KLDO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1,000 shs
Average Volume
11,644 shs
Market Capitalization
$426 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

Kaleido Biosciences Inc (KLDO)
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Kaleido Biosciences (OTC: KLDO)
See More Headlines

KLDO Stock Analysis - Frequently Asked Questions

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The company earned $0.10 million during the quarter, compared to analysts' expectations of $0.25 million.

Kaleido Biosciences (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), COMPASS Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB).

Company Calendar

Last Earnings
11/01/2021
Today
8/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Software
Current Symbol
NASDAQ:KLDO
CIK
1751299
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.10 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
42,623,000
Free Float
38,787,000
Market Cap
$426 thousand
Optionable
Not Optionable
Beta
-0.06

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:KLDO) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners